Oncology Medical News about breast cancer;resistance to Tamoxifen treatment

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression of ER-α36, a novel variant of estrogen receptor-α, and resistance to tamoxifen treatment in breast cancer
Journal of Clinical Oncology, 06/04/09

Shi L et al. - In a study to investigate the association between ER-α36 expression and tamoxifen resistance in pts with breast cancer, it was reported that women with ER-α66–positive tumors that also express high levels of ER-α36 are less likely to benefit from tamoxifen treatment.

Methods

ER-α36 protein expression in tumors from 896 women (2 independent cohorts, 1 and 2) with operable primary breast cancer was assessed using an immunohistochemistry assay.

Results

In the first cohort of 710 consecutive pts, overexpression of ER-α36 was associated with poorer disease-free survival (DFS) and disease-specific survival (DSS) in pts with ER-α66–positive tumors who received tamoxifen treatment (chemotherapy plus tamoxifen or tamoxifen alone, n=307).
ER-α36 was not associated with survival in pts with ER-α66–positive tumors who did not receive tamoxifen (chemotherapy alone, n=129) and in pts with ER-α66–negative tumors whether they received tamoxifen (n = 73) or not (n = 149).
In the second cohort of 186 pts who only received tamoxifen as adjuvant therapy, overexpression of ER-α36 was significantly associated with poorer DFS and DSS in 156 ER-α66–positive pts from this cohort, and ER-α36 remained an independent unfavorable factor for both DFS and DSS in these 156 pts by a multivariate analysis.

<< Previous
The association of nonalcoholic steatohepatitis and tamoxifen in...

Next >>
Complement of peritumoral and subareolar injection in breast...